Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, researchers demonstrated that treating platelet rich plasma with microsecond pulsed electric fields effectively activates platelets and induces similar or higher growth factor release compared to traditional bovine thrombin, suggesting a potential clinical use that may be more cost-effective and practical.

In this study, a 49-year-old female with metastatic adrenocortical carcinoma experienced an abscopal effect following pulse electric field ablation, suggesting potential as an adjunct to systemic immunotherapy for liver tumors.

Post-finasteride syndrome causes various symptoms in men using finasteride, with no known cure.

This study analyzed 3,295 cases from the FDA Adverse Event Reporting System to describe demographics and reporting trends of post-finasteride syndrome, finding that most reports came from patients rather than health professionals.

In this study, researchers found no evidence of hemodynamic alterations associated with erectile dysfunction in men self-diagnosed with post-finasteride syndrome following the use of finasteride for hair loss.

This policy brief reports that post-drug syndromes like Post-Finasteride Syndrome are largely overlooked in current pharmacovigilance systems, which prioritize acute drug reactions, resulting in inadequate recognition and management of persistent medication-induced conditions.

This review examines global literature on post-finasteride syndrome, finding few studies link finasteride to rare sexual and systemic adverse effects; it is the first such review conducted in Spain.

This study observed that higher PFAS concentrations during adolescence were linked to later pubertal development and lower estradiol levels in females, but not in males, potentially due to PFAS excretion with menstrual fluid.

This commentary reviews the post-Finasteride syndrome and argues that while the condition's validity is debated, comprehensive guidelines are needed to address related risks and treatment options; it reports no new clinical results.

This review examines the contentious issue of post-finasteride syndrome linked to 5-alpha reductase inhibitors and reports mixed findings on its sexual, physical, and psychological effects; the authors call for more rigorous studies.

This study found that patients with post-finasteride syndrome exhibited major depressive disorder, severe erectile dysfunction, and neuropathy, alongside altered neuroactive steroid levels in cerebrospinal fluid.

This case study describes a 45-year-old man who developed post-finasteride syndrome with various symptoms after stopping Finasteride, highlighting the condition's rarity and poorly understood pathophysiology.

In this study, finasteride was found to induce tissue-specific P-glycoprotein activity in the liver and kidney of rabbits after a 14-day treatment period.

In this study, dermatologists from the Spanish Hair and Nail Disorders Group viewed post-finasteride syndrome as rare and primarily of psychiatric origin, with limited scientific evidence supporting its existence.

This review discusses adverse effects of 5 alpha-reductase inhibitors, particularly persistent side effects such as post-finasteride syndrome, and highlights the need for further investigation.

This study aimed to identify characteristics of patients who fail to void during pressure-flow studies, which limits the determination of the cause behind their lower urinary tract symptoms.

This policy brief found that post-drug syndromes are under-recognized in current pharmacovigilance systems, leading to inadequate risk assessments and prolonged patient harm from persistent drug-induced conditions.

This article evaluates clinical and scientific literature on post-finasteride syndrome, concluding that finasteride and dutasteride may cause persistent sexual, neurological, and physical adverse side effects in a subset of men.

This study examined data from the FDA Adverse Event Reporting System and found that finasteride use is linked with both known and previously unlisted adverse events, such as erectile dysfunction and post-5α reductase inhibitor syndrome, with variations observed by age and sex.

This study found significant differences in gene expression, particularly in androgen receptor activity, between men with post-finasteride syndrome and healthy controls, suggesting a potential biological basis for the syndrome.

This review discusses the occurrence of persistent sexual, physical, neurological, and psychiatric side effects known as post-finasteride syndrome after 5x-reductase inhibitor treatment, and emphasizes the importance of evaluating these risks for patients with benign prostatic hyperplasia or androgenic alopecia.

This article reviews evidence- and consensus-based recommendations for using pegvaliase in adults with PKU and reports no new clinical results.

This study examines how conditions like PSSD, Long COVID, and ME/CFS form a "Post-Exposure Syndromes" family, initiated by transient exposures but persisting due to complex state-space dynamics, and suggests improving pharmacovigilance to better address and understand these persistent syndromes.

This review discusses post-finasteride syndrome, emphasizing its serious psychological and cognitive symptoms and the need for more research and awareness in the medical community, but provides no new clinical findings.

Some men experience persistent sexual, neurological, and psychological symptoms after stopping finasteride, but evidence of permanent damage is inconclusive.

Finasteride's link to health issues like male breast cancer, infertility, and prostate cancer needs more research through placebo-controlled trials to confirm.

This review examines the clinicopathologic features of perifollicular elastolysis and indicates that, while its presentation is consistent, there is a lack of high-certainty evidence for effective treatments.

This article summarizes Dr. Alan Jacobs's presentation at the 2016 ISHRS World Congress but reports no new research findings.

This case report describes a 26-year-old man who experienced persistent sexual dysfunction and other symptoms for 19 months after stopping finasteride for androgenetic alopecia. The authors highlight post-finasteride syndrome's impact on quality of life and stress the need for careful risk-benefit assessment before prescribing.

This policy brief highlights that post-drug syndromes remain under-recognized in pharmacovigilance, leading to inadequate risk assessments and patient care. It identifies systemic failures in current frameworks and recommends actions to improve long-term drug safety monitoring and education, affecting public health outcomes significantly.